FIELD: medicine.
SUBSTANCE: described NASP may be introduced as independent agents or in combination with other medications (such as factors VIII and VIIIa) to provide hemostasis. Method is also described for treatment of individual, who needs improvement of coagulation, which includes introduction of therapeutically efficient amount of composition containing non-anticoagulating sulphated polysaccharide (NASP) to specified individual.
EFFECT: wide range of procoagulant agent application.
19 cl, 8 dwg, 13 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST INHIBITOR OF TISSUE FACTOR METABOLIC PATHWAY | 2009 |
|
RU2562114C2 |
| DOSING REGIMEN FOR TFPI ANTAGONISTS | 2019 |
|
RU2780590C1 |
| PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VIIA AND FACTOR XIII | 2001 |
|
RU2272648C2 |
| AGENT ELICITING ANTICOAGULATING AND IMMUNOTROPIC EFFECT | 2002 |
|
RU2247574C2 |
| FACTOR II AND FIBRINOGEN FOR TREATMENT OF HAEMOSTATIC DISORDERS | 2011 |
|
RU2606155C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING FACTOR VII POLYPEPTIDES AND FACTOR XI POLYPEPTIDES | 2002 |
|
RU2298416C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND USE THEREOF | 2016 |
|
RU2705540C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| MODIFIED FACTOR VII-BASED POLYPEPTIDES AND THEREOF APPLICATION | 2008 |
|
RU2571931C2 |
| PHARMACEUTICAL PREPARATION THAT IS ABLE TO ACCELERATE BLOOD COAGULATION PROCESS, A METHOD OF BLOOD COAGULATION ACCELERATION IN VITRO, USE OF AN INHIBITOR OF EPI-ACTIVITY AS A SUBSTANCE ACCELERATING BLOOD COAGULATION PROCESS | 1991 |
|
RU2127600C1 |
